- Home
- VTEX vs GHRS Comparison
VTEX vs GHRS Comparison
Compare VTEX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTEX
- GHRS
- Stock Information
- Founded
- VTEX 1999
- GHRS 2018
- Country
- VTEX Cayman Islands
- GHRS Ireland
- Employees
- VTEX N/A
- GHRS N/A
- Industry
- VTEX Computer Software: Prepackaged Software
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- VTEX Technology
- GHRS Health Care
- Exchange
- VTEX Nasdaq
- GHRS Nasdaq
- Market Cap
- VTEX 791.5M
- GHRS 774.1M
- IPO Year
- VTEX 2021
- GHRS 2021
- Fundamental
- Price
- VTEX $4.42
- GHRS $14.49
- Analyst Decision
- VTEX Strong Buy
- GHRS Strong Buy
- Analyst Count
- VTEX 5
- GHRS 9
- Target Price
- VTEX $7.16
- GHRS $29.33
- AVG Volume (30 Days)
- VTEX 1.1M
- GHRS 280.2K
- Earning Date
- VTEX 11-06-2025
- GHRS 11-07-2025
- Dividend Yield
- VTEX N/A
- GHRS N/A
- EPS Growth
- VTEX 48.79
- GHRS N/A
- EPS
- VTEX 0.05
- GHRS N/A
- Revenue
- VTEX $230,497,000.00
- GHRS N/A
- Revenue This Year
- VTEX $9.30
- GHRS N/A
- Revenue Next Year
- VTEX $13.22
- GHRS N/A
- P/E Ratio
- VTEX $86.12
- GHRS N/A
- Revenue Growth
- VTEX 4.53
- GHRS N/A
- 52 Week Low
- VTEX $3.92
- GHRS $6.72
- 52 Week High
- VTEX $6.97
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- VTEX 51.99
- GHRS 55.65
- Support Level
- VTEX $4.28
- GHRS $12.50
- Resistance Level
- VTEX $4.51
- GHRS $14.44
- Average True Range (ATR)
- VTEX 0.14
- GHRS 0.95
- MACD
- VTEX 0.02
- GHRS 0.07
- Stochastic Oscillator
- VTEX 67.02
- GHRS 80.07
About VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.